MyFinsight
Home
Blog
About
Contact
Proceeds from the
issuance of common stock...
$19,907K
Proceeds from the
exercise of stock options
$27K
Net cash provided by
financing activities
$19,934K
Net (decrease)
increase in cash and cash...
-$4,086K
Canceled cashflow
$19,934K
Stock-based compensation
$3,924K
Depreciation
$157K
Non-cash lease expense
$69K
Proceeds from maturities
of investment...
$45,000K
Net cash used in
operating activities
-$16,431K
Canceled cashflow
$4,150K
Net cash (used in)
provided by investing...
-$7,589K
Canceled cashflow
$45,000K
Net loss
-$17,636K
Accounts payable and
other liabilities
-$2,511K
Prepaid expense and
other assets
$287K
Amortization of premiums on
investment securities, net
$147K
Purchases of investment
securities
$52,589K
Back
Back
Cash Flow
Design Therapeutics, Inc. (DSGN)
Design Therapeutics, Inc. (DSGN)
source: myfinsight.com